ch.oddb.org
 
Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
H05BX02 - ParicalcitolATC-DDD Version 2016. Source: WHO
H - Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins

This group comprises all hormonal preparations for systemic use, except:
- Insulins, see A10.
- Anabolic steroids, see A14.
- Catecholamines, see C01C and R03C.
- Sex hormones, see G03.
- Sex hormones used in treatment of neoplastic diseases, see L02.
- Metreleptin used for treatment of complications of leptin deficiency in patients with generalised lipodystrophy is classified in A16AA.

The DDDs are generally based on the treatment or diagnosis of endocrine disorders.

H05 - Calcium Homeostasis

Drugs acting on calcium homeostasis are classified in this group.
Vitamin-D preparations, see A11CC.

H05B - Anti-Parathyroid Agents
 
H05BX - Other Anti-Parathyroid Agents

Paricalcitol and doxercalciferol indicated for the prevention and treatment of secondary hyperparathyroidism are classified here.
Oral formulations of calcifediol, solely approved for treatment of renal secondary hyperparathyroidism are classified here, while all other pharmaceutical formulations of calcifediol are classified in A11CC06.

The DDD for cinacalcet is based on the treatment of secondary hyperparathyroidism.

H05BX02 - Paricalcitol
StärkeAdm.RouteNote
 P 
 O 
2023 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home